Open AccessTyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
Author(s) -
Juejun Gong,
Li Zhang
Publication year - 2020
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0000000000000696
Subject(s) - medicine , tolerability , lung cancer , oncology , clinical trial , adverse effect , tyrosine kinase , targeted therapy , tyrosine kinase inhibitor , cancer , intensive care medicine , receptor
TKI therapy has shown excellent efficacy and favorable tolerability in patients with mutation-positive nonsmall cell lung cancer. However, there is no clear consensus on the role of TKI as induction therapy. In this article, we reviewed recently published studies to analyze the benefits of tyrosine kinase inhibitors, in particular, EGFR TKIs and ALK TKIs, as inducible treatments for NSCLC.